ci 988 has been researched along with naltrexone in 2 studies
Studies (ci 988) | Trials (ci 988) | Recent Studies (post-2010) (ci 988) | Studies (naltrexone) | Trials (naltrexone) | Recent Studies (post-2010) (naltrexone) |
---|---|---|---|---|---|
147 | 8 | 14 | 8,745 | 1,228 | 2,642 |
Protein | Taxonomy | ci 988 (IC50) | naltrexone (IC50) |
---|---|---|---|
Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
Delta-type opioid receptor | Mus musculus (house mouse) | 0.0051 | |
Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0063 | |
Kappa-type opioid receptor | Mus musculus (house mouse) | 0.006 | |
Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
Mu-type opioid receptor | Homo sapiens (human) | 0.006 | |
Delta-type opioid receptor | Homo sapiens (human) | 0.0319 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0093 | |
Kappa-type opioid receptor | Homo sapiens (human) | 0.0377 | |
Mu-type opioid receptor | Mus musculus (house mouse) | 0.0076 | |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0004 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Blommaert, A; Fournié-Zaluski, MC; Noble, F; Roques, BP | 1 |
Boucher, M; Coudoré-Civiale, MA; Eschalier, A; Fournié-Zaluski, MC; Méen, M; Roques, BP | 1 |
2 other study(ies) available for ci 988 and naltrexone
Article | Year |
---|---|
A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
Topics: Analgesics; Animals; Disulfides; Enkephalins; Formaldehyde; Indoles; Male; Meglumine; Mice; Morphine; Naloxone; Naltrexone; Pain Measurement; Phenylalanine; Receptors, Cholecystokinin; Receptors, Opioid, delta; Receptors, Opioid, mu | 1995 |
Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
Topics: Aminopeptidases; Animals; Diabetes Mellitus, Experimental; Disulfides; Drug Synergism; Indoles; Male; Meglumine; Naloxone; Naltrexone; Neprilysin; Pain; Pain Measurement; Phenylalanine; Pressure; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Time Factors; Vocalization, Animal; Weight Loss | 2001 |